002082 万邦德
已收盘 12-20 15:00:00
资讯
新帖
简况
万邦德(002082)12月19日主力资金净买入227.28万元
证券之星 · 12-19
万邦德(002082)12月19日主力资金净买入227.28万元
万邦德:12月18日接受机构调研,浙商证券、台州市国有资产投资等多家机构参与
证券之星 · 12-19
万邦德:12月18日接受机构调研,浙商证券、台州市国有资产投资等多家机构参与
【私募调研记录】澜胜资产调研万邦德
证券之星 · 12-19
【私募调研记录】澜胜资产调研万邦德
万邦德(002082.SZ):WP103(石杉碱甲注射液)临床试验申请获得FDA受理
智通财经 · 12-17
万邦德(002082.SZ):WP103(石杉碱甲注射液)临床试验申请获得FDA受理
万邦德:子公司WP103药品临床试验申请获得FDA受理
美港电讯 · 12-17
万邦德:子公司WP103药品临床试验申请获得FDA受理
万邦德(002082.SZ):WP107药品临床试验申请获得FDA受理
智通财经 · 12-15
万邦德(002082.SZ):WP107药品临床试验申请获得FDA受理
万邦德最新公告:子公司WP107药品临床试验申请获得FDA受理
证券之星 · 12-15
万邦德最新公告:子公司WP107药品临床试验申请获得FDA受理
万邦德最新公告:拟设立全资子公司 促进公司医药大健康产业战略发展
证券之星 · 12-13
万邦德最新公告:拟设立全资子公司 促进公司医药大健康产业战略发展
万邦德(002082.SZ)完成设立全资子公司浙江万邦德工贸事项
智通财经 · 12-13
万邦德(002082.SZ)完成设立全资子公司浙江万邦德工贸事项
万邦德(002082)12月5日主力资金净卖出532.71万元
证券之星 · 12-05
万邦德(002082)12月5日主力资金净卖出532.71万元
A股中药板块短线拉升,精华制药封板涨停,金花股份、葫芦娃此前封板,粤万年青、盘龙药业、红日药业、万邦德、特一药业等跟涨。
美港电讯 · 11-26
A股中药板块短线拉升,精华制药封板涨停,金花股份、葫芦娃此前封板,粤万年青、盘龙药业、红日药业、万邦德、特一药业等跟涨。
【机构调研记录】工银瑞信基金调研万邦德、天奈科技等5只个股(附名单)
证券之星 · 11-25
【机构调研记录】工银瑞信基金调研万邦德、天奈科技等5只个股(附名单)
万邦德:创新成果显著 产业升级启动新增长
中国财富通 · 11-22
万邦德:创新成果显著 产业升级启动新增长
万邦德:申万证券、上海远希私募基金管理有限公司等多家机构于11月21日调研我司
证券之星 · 11-22
万邦德:申万证券、上海远希私募基金管理有限公司等多家机构于11月21日调研我司
中国原创药石杉碱甲打破国际竞争 进军万亿级阿尔茨海默病治疗市场
中国财富通 · 11-19
中国原创药石杉碱甲打破国际竞争 进军万亿级阿尔茨海默病治疗市场
万邦德(002082.SZ):获得盐酸氯丙嗪片药品补充申请批准通知书
智通财经网 · 11-17
万邦德(002082.SZ):获得盐酸氯丙嗪片药品补充申请批准通知书
万邦德最新公告:全资子公司药品获得一致性评价注册批件
证券之星 · 11-17
万邦德最新公告:全资子公司药品获得一致性评价注册批件
A股中药股拉升走强,维康药业、万邦德、康惠制药涨停,特一药业、华润三九、香雪制药等跟涨。
美港电讯 · 11-12
A股中药股拉升走强,维康药业、万邦德、康惠制药涨停,特一药业、华润三九、香雪制药等跟涨。
A股医药医疗股震荡反弹,药易购、康惠制药、万邦德、国际医学、新里程、塞力医疗、合富中国、开开实业等多股涨停,普瑞眼科、漱玉平民等涨超10%。
美港电讯 · 11-12
A股医药医疗股震荡反弹,药易购、康惠制药、万邦德、国际医学、新里程、塞力医疗、合富中国、开开实业等多股涨停,普瑞眼科、漱玉平民等涨超10%。
异动快报:万邦德(002082)11月12日9点49分触及涨停板
证券之星 · 11-12
异动快报:万邦德(002082)11月12日9点49分触及涨停板
加载更多
公司概况
公司名称:
万邦德医药控股集团股份有限公司
所属行业:
医药制造业
上市日期:
2006-11-20
主营业务:
万邦德医药控股集团股份有限公司主营业务为现代中药、化学原料药及化学制剂的研发、生产和销售以及提供高端医疗器械研制、医疗设备服务和提供医院工程服务。主要产品是心脑血管系统主导产品、神经系统主导产品、呼吸系统主导产品、消化系统主导产品、精神系统主导产品、骨科植入器械、医疗设备及医院工程服务、一次性无菌医用高分子耗材、防护用品。
发行价格:
6.36
{"stockData":{"symbol":"002082","market":"SZ","secType":"STK","nameCN":"万邦德","latestPrice":7.05,"timestamp":1734678219000,"preClose":6.96,"halted":0,"volume":11821800,"delay":0,"floatShares":617000000,"shares":617000000,"eps":0.1653,"marketStatus":"已收盘","marketStatusCode":5,"change":0.09,"latestTime":"12-20 15:00:00","open":6.98,"high":7.15,"low":6.95,"amount":83237500,"amplitude":0.0287,"askPrice":7.05,"askSize":2271,"bidPrice":7.04,"bidSize":164,"shortable":0,"etf":0,"ttmEps":0.1653,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":6.96,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":7.66,"lowLimit":6.26,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":616689055,"pbRate":1.61,"roa":"--","roe":"1.7%","epsLYR":0.08,"committee":-0.623554,"marketValue":4348000000,"floatMarketCap":4348000000,"peRate":42.649729,"changeRate":0.0129,"turnoverRate":0.0192,"status":0},"requestUrl":"/m/hq/s/002082","defaultTab":"news","newsList":[{"id":"2492495110","title":"万邦德(002082)12月19日主力资金净买入227.28万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492495110","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492495110?lang=zh_cn&edition=full","pubTime":"2024-12-19 15:31","pubTimestamp":1734593495,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月19日收盘,万邦德报收于6.96元,下跌3.06%,换手率1.72%,成交量10.61万手,成交额7452.07万元。12月19日的资金流向数据方面,主力资金净流入227.28万元,占总成交额3.05%,游资资金净流出98.88万元,占总成交额1.33%,散户资金净流出128.41万元,占总成交额1.72%。万邦德主营业务:医药制造、医疗器械大健康产业。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900020762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0050","002082","BK0239","BK0028","BK0004"],"gpt_icon":0},{"id":"2492916001","title":"万邦德:12月18日接受机构调研,浙商证券、台州市国有资产投资等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2492916001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492916001?lang=zh_cn&edition=full","pubTime":"2024-12-19 11:04","pubTimestamp":1734577441,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年12月18日万邦德发布公告称公司于2024年12月18日接受机构调研,浙商证券、台州市国有资产投资、杭州久胜私募基金管理、浙江怀信资产管理、杭州厚邦投资、台州科创集团、中金公司、东北证券、国金证券、万乘私募基金、拓牌基金、上海师正投资、澜胜资产、四川大决策投资参与。万邦德医疗“引进来,走出去”国际化发展战略初显成效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900014581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601878","002082","BK0239","BK0050","BK0004","BK0028","BK0276"],"gpt_icon":0},{"id":"2492617101","title":"【私募调研记录】澜胜资产调研万邦德","url":"https://stock-news.laohu8.com/highlight/detail?id=2492617101","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492617101?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:02","pubTimestamp":1734566540,"startTime":"0","endTime":"0","summary":"根据市场公开信息及12月18日披露的机构调研信息,知名私募澜胜资产近期对1家上市公司进行了调研,相关名单如下:1)万邦德 (澜胜资产参与公司特定对象调研&现场参观)个股亮点:公司与盈科瑞(天津)创新医药研究有限公司联合开发1.1类中药创新药理中消痞颗粒的临床研究及未来的产业化。;公司在售产品联苯双酯滴丸适应症为临床用于慢性迁延型肝炎伴ALT升高者;公司医疗器械主要涉及一次性无菌医用高分子器械、口罩防护用品等业务证券之星点评:澜胜资产,拥有沈力勤等知名基金经理。本次调研的上市公司平均市盈率43.46。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2024121900007311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002082","BK0050","BK0004","BK0239"],"gpt_icon":0},{"id":"2492569959","title":"万邦德(002082.SZ):WP103(石杉碱甲注射液)临床试验申请获得FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2492569959","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492569959?lang=zh_cn&edition=full","pubTime":"2024-12-17 20:28","pubTimestamp":1734438521,"startTime":"0","endTime":"0","summary":"智通财经APP讯,万邦德 发布公告,公司全资子公司万邦德制药集团有限公司于2024年12月17日收到美国食品药品监督管理局的书面回复,公司自主研发的WP103用于治疗新生儿缺氧缺血性脑病的临床试验申请正式获得受理。WP103是公司创新药研发团队基于临床前、临床数据,自主研发的治疗新生儿缺氧缺血性脑病的符合FDA要求的石杉碱甲注射液,目前美国尚无石杉碱甲药品获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK1576","002082","BK0239","BK0004","BK0050","03347","BK1141","BK1583"],"gpt_icon":0},{"id":"2492785956","title":"万邦德:子公司WP103药品临床试验申请获得FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2492785956","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492785956?lang=zh_cn&edition=full","pubTime":"2024-12-17 20:20","pubTimestamp":1734438053,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["01477","HIE","06978","03347","BK0050","BK1574","BK1191","BK0028","002082","BK0239","159992","BK1161","BK1141","BK1583","BK1576","BK0004"],"gpt_icon":0},{"id":"2491526381","title":"万邦德(002082.SZ):WP107药品临床试验申请获得FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2491526381","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491526381?lang=zh_cn&edition=full","pubTime":"2024-12-15 17:19","pubTimestamp":1734254345,"startTime":"0","endTime":"0","summary":"智通财经APP讯,万邦德(002082.SZ)公告,公司全资子公司万邦德制药集团有限公司于2024年12月15日收到美国食品药品监督管理局(简称“FDA”)的书面回复,公司自主研发的WP107(石杉碱甲口服溶液)用于治疗“全身型重症肌无力”的临床试验申请正式获得受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0004","BK1576","03347","BK1583","002082","BK0050","BK1141","BK0239"],"gpt_icon":0},{"id":"2491231995","title":"万邦德最新公告:子公司WP107药品临床试验申请获得FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2491231995","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491231995?lang=zh_cn&edition=full","pubTime":"2024-12-15 16:30","pubTimestamp":1734251425,"startTime":"0","endTime":"0","summary":"万邦德公告,全资子公司万邦德制药集团有限公司于2024年12月15日收到美国食品药品监督管理局(FDA)的书面回复,公司自主研发的WP107(石杉碱甲口服溶液)用于治疗“全身型重症肌无力”的临床试验申请正式获得受理。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121500001861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0050","BK1141","BK0239","BK0028","BK1576","002082","BK1583","BK0004","03347"],"gpt_icon":0},{"id":"2491272345","title":"万邦德最新公告:拟设立全资子公司 促进公司医药大健康产业战略发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2491272345","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491272345?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:35","pubTimestamp":1734078947,"startTime":"0","endTime":"0","summary":"万邦德公告,为公司医药大健康产业战略发展需要,公司决定以自有资金投资设立全资子公司浙江万邦德工贸有限公司,注册资本为1000万元。公司已取得温岭市市场监督管理局核发的营业执照。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300028303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK0028","BK1515","002082","BK0050","BK0004","BK0239","BK1161","159938","BK1574"],"gpt_icon":0},{"id":"2491585310","title":"万邦德(002082.SZ)完成设立全资子公司浙江万邦德工贸事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2491585310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491585310?lang=zh_cn&edition=full","pubTime":"2024-12-13 15:45","pubTimestamp":1734075957,"startTime":"0","endTime":"0","summary":"智通财经APP讯,万邦德(002082.SZ)公告,公司决定以自有资金投资设立全资子公司浙江万邦德工贸有限公司,注册资本为人民币1000万元。公司已取得温岭市市场监督管理局核发的营业执照。公告显示,本次设立全资子公司主要是为了进一步响应国家“一带一路”倡议,持续推进公司“引进来,走出去”中非协同发展的战略。加强与非洲健康产业的紧密连接,提升公司在大健康产业的综合实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002082","BK0050","BK0028","BK0004"],"gpt_icon":0},{"id":"2489486695","title":"万邦德(002082)12月5日主力资金净卖出532.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489486695","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489486695?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:28","pubTimestamp":1733383699,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月5日收盘,万邦德报收于6.48元,下跌1.82%,换手率1.56%,成交量9.6万手,成交额6214.29万元。12月5日的资金流向数据方面,主力资金净流出532.71万元,占总成交额8.57%,游资资金净流出16.62万元,占总成交额0.27%,散户资金净流入549.32万元,占总成交额8.84%。万邦德主营业务:医药制造、医疗器械大健康产业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500020224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","002082","BK0050","BK0028","BK0239"],"gpt_icon":0},{"id":"2486912013","title":"A股中药板块短线拉升,精华制药封板涨停,金花股份、葫芦娃此前封板,粤万年青、盘龙药业、红日药业、万邦德、特一药业等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2486912013","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486912013?lang=zh_cn&edition=full","pubTime":"2024-11-26 11:10","pubTimestamp":1732590630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002728","600080","399300","BK0102","BK0239","BK0077","BK0028","BK0050","159982","BK0188","BK0004","BK0201","002082","301111","300026","002864","002349","605199"],"gpt_icon":0},{"id":"2486373743","title":"【机构调研记录】工银瑞信基金调研万邦德、天奈科技等5只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2486373743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486373743?lang=zh_cn&edition=full","pubTime":"2024-11-25 08:01","pubTimestamp":1732492906,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月22日披露的机构调研信息,工银瑞信基金近期对5家上市公司进行了调研,相关名单如下:1)万邦德 个股亮点:公司与盈科瑞(天津)创新医药研究有限公司联合开发1.1类中药创新药理中消痞颗粒的临床研究及未来的产业化。工银瑞信基金成立于2005年,截至目前,资产管理规模8002.2亿元,排名13/208;资产管理规模3896.86亿元,排名14/208;管理公募基金数453只,排名12/208;旗下公募基金经理79人,排名11/208。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500001162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0229","002082","BK0004","BK0239","BK0050","688116"],"gpt_icon":0},{"id":"2485406709","title":"万邦德:创新成果显著 产业升级启动新增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2485406709","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485406709?lang=zh_cn&edition=full","pubTime":"2024-11-22 11:16","pubTimestamp":1732245380,"startTime":"0","endTime":"0","summary":"万邦德医药研究院院长赵冠甲博士重点介绍了石杉碱甲等创新药物的研发进展和成果。这些交流加深了投资者对万邦德创新成果和投资价值的认识。分析人士指出,通过本次交流会,展示了万邦德医药控股集团在医药健康领域的创新能力、研发成果以及国际市场的前景,表达了与投资者共同成长的决心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=I5k8hCLtYC4%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0028","BK0050","BK0004","002082"],"gpt_icon":0},{"id":"2485405260","title":"万邦德:申万证券、上海远希私募基金管理有限公司等多家机构于11月21日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2485405260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485405260?lang=zh_cn&edition=full","pubTime":"2024-11-22 11:03","pubTimestamp":1732244595,"startTime":"0","endTime":"0","summary":"公司积极推进与中国 CDE、美国 FD 等药监部门展开沟通交流,有望尽快启动支持新药上市申请的注册临床研究。公司开展的一期临床研究中,也未出现严重不良反应。通过真实世界的研究,收集临床数据的有效性及安全性的同时,从而带动学术推广,建立全国神经系统专家支持体系,将为公司石杉碱甲控释片上市后的为痴呆患者序贯治疗奠定市场基础。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200014247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["163113","002082","BK0239","BK0004","BK0050","BK0028"],"gpt_icon":0},{"id":"2484953315","title":"中国原创药石杉碱甲打破国际竞争 进军万亿级阿尔茨海默病治疗市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2484953315","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484953315?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:43","pubTimestamp":1731980639,"startTime":"0","endTime":"0","summary":"在全球医药研发的激烈角逐中,阿尔茨海默病治疗领域一直是备受关注的焦点。业内人士指出,近年,中国完全原创新药石杉碱甲不断取得研发突破,有望打破国际竞争格局,向规模预计高达数万亿的AD治疗市场发起有力冲击,为全球患者带来新的治疗选择。石杉碱甲作为中国原创药,在欧美已开展治疗AD的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=OyaLD17wDdg%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","MCI","BK0239","002082","BK0004","BK0050"],"gpt_icon":0},{"id":"2484304688","title":"万邦德(002082.SZ):获得盐酸氯丙嗪片药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2484304688","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484304688?lang=zh_cn&edition=full","pubTime":"2024-11-17 16:47","pubTimestamp":1731833227,"startTime":"0","endTime":"0","summary":"万邦德(002082.SZ)发布公告,公司全资子公司万邦德制药集团有限公司于近日收...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002082","BK0004","BK0050","BK0239","BK0028"],"gpt_icon":0},{"id":"2484500127","title":"万邦德最新公告:全资子公司药品获得一致性评价注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2484500127","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484500127?lang=zh_cn&edition=full","pubTime":"2024-11-17 16:30","pubTimestamp":1731832210,"startTime":"0","endTime":"0","summary":"万邦德公告,全资子公司万邦德制药集团有限公司近日收到国家药品监督管理局核准签发的关于盐酸氯丙嗪片的《药品补充申请批准通知书》。该药品通过仿制药质量和疗效一致性评价,系国内首家通过。公司将加快该药品市场推广,对公司经营发展具有积极作用。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111700001108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0050","002082","BK0239","BK0028","BK0004"],"gpt_icon":0},{"id":"2482219790","title":"A股中药股拉升走强,维康药业、万邦德、康惠制药涨停,特一药业、华润三九、香雪制药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2482219790","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482219790?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:00","pubTimestamp":1731376839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0070","000999","BK0028","300147","BK0188","BK0175","399300","002082","BK0004","BK0196","603139","159982","BK0060","BK0050","BK0201","BK0010","BK0183","BK0239","002728","300878","BK0185","BK0012"],"gpt_icon":0},{"id":"2482797227","title":"A股医药医疗股震荡反弹,药易购、康惠制药、万邦德、国际医学、新里程、塞力医疗、合富中国、开开实业等多股涨停,普瑞眼科、漱玉平民等涨超10%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2482797227","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482797227?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:51","pubTimestamp":1731376276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002082","301239","300937","BK0050","BK0239","BK0184","BK0188","BK1161","603122","BK0077","BK0004","09939","BK0114","BK0250","BK0181","159891","301017","BK0099","BK0028","600272","603716","BK0096","BK0146","399300","BK0209","BK1515","BK0042","603139","BK1574","BK0236","000516","159938","BK0046","159982","002219"],"gpt_icon":0},{"id":"2482790464","title":"异动快报:万邦德(002082)11月12日9点49分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2482790464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482790464?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:50","pubTimestamp":1731376236,"startTime":"0","endTime":"0","summary":"证券之星11月12日盘中消息,9点49分万邦德(002082)触及涨停板。目前价格6.56,上涨10.07%。其所属行业中药目前上涨。领涨股为康惠制药。该股为新冠药物,流感,中药概念热股,当日新冠药物概念上涨2.08%,流感概念上涨1.73%,中药概念上涨1.65%。11月11日的资金流向数据方面,主力资金净流入452.22万元,占总成交额5.03%,游资资金净流入225.95万元,占总成交额2.51%,散户资金净流出678.17万元,占总成交额7.54%。近5日资金流向一览见下表:万邦德主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200009594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0004","BK0028","002082","BK0050"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2006-11-20","address":"浙江省湖州市吴兴区织里镇栋梁路1688号","stockEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.1298},{"period":"3month","weight":0.7537},{"period":"6month","weight":0.638},{"period":"1year","weight":0.1305},{"period":"ytd","weight":0.1235}],"companyName":"万邦德医药控股集团股份有限公司","boardCode":"AI0027","perCapita":"27081股","boardName":"医药制造业","registeredCapital":"61668万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 万邦德医药控股集团股份有限公司主营业务为现代中药、化学原料药及化学制剂的研发、生产和销售以及提供高端医疗器械研制、医疗设备服务和提供医院工程服务。主要产品是心脑血管系统主导产品、神经系统主导产品、呼吸系统主导产品、消化系统主导产品、精神系统主导产品、骨科植入器械、医疗设备及医院工程服务、一次性无菌医用高分子耗材、防护用品。","serverTime":1734885615113,"listedPrice":6.36,"stockholders":"204204人(较上一季度增加592.66%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万邦德(002082)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万邦德(002082)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万邦德,002082,万邦德股票,万邦德股票老虎,万邦德股票老虎国际,万邦德行情,万邦德股票行情,万邦德股价,万邦德股市,万邦德股票价格,万邦德股票交易,万邦德股票购买,万邦德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万邦德(002082)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万邦德(002082)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}